KV1.5 channel blockers selectively prolong atrial refractoriness without inducing ventricular proarrhythmic effects (8), making KV1.5 a promising pharmacological target for the treatment of AF (10, 11, 12, 13). The gene discussed is KCNA5; the disease is atrial fibrillation.